Cellular Logistics Awarded Second NIH Phase I SBIR grant

Cellular Logistics Awarded Second NIH Phase I SBIR grant

MADISON, Wis., October 24, 2022 – Cellular Logistics has been awarded a $337,000 SBIR grant from the National Institutes of Health to further evaluate the functional immune and angiogenic (blood vessel growth) responses of the company’s Cardiac Fibroblast Matrix product, CFX™ Solus, for the treatment of early post-myocardial infarction, more commonly known as a heart attack.

“This exciting project will enhance our understanding of the cell-signaling mechanisms of how CFX™ Solus modulates the localized immune system and promotes the repair of damaged heart tissue”, says Alex Vodenlich, president, and chief executive officer.

CFX™ Solus, is a highly promising formulation of a regenerative medicine biomaterial designed to minimize injury and revitalize damaged heart tissue for patients suffering a heart attack. Suffering a heart attack can lead to a more serious condition, heart failure, which is a leading cause of death and hospitalization in the United States. Over six million Americans currently suffer from heart failure and this number is expected to exceed eight million by 2030.

“We have shown that CFX™ Solus modifies macrophages to take on a more reparative role, and with extremely promising initial data in animal models we now aim to translate this into improvements in heart perfusion and function following a heart attack,” said Dr. Eric Schmuck, vice president, and chief scientific officer of Cellular Logistics. “For the millions of people worldwide who suffer from heart failure following a recent heart attack, this could be an incredible game changer”, says Dr. Schmuck.

Cellular Logistics CFX™ technology will also create unique opportunities for combination therapies using stem cells and other therapeutic modalities for treating cardiovascular disease.


About Cellular Logistics

Cellular Logistics, Inc. is dedicated to improving the lives of individuals suffering from cardiovascular disease. CL was founded in 2016 by a multi-disciplinary clinical and scientific team from the University of Wisconsin-Madison School of Medicine and Public Health. The company’s vision is to help create a world where a new generation of therapies can reverse the debilitating symptoms of cardiovascular diseases, dramatically reducing re-hospitalization, and enabling patients to live longer, healthier lives. Cellular Logistics holds an exclusive license from the Wisconsin Alumni Research Foundation (WARF) to the CFX™ technology.

Press Contact: Alex Vodenlich, alex@cellogistics.com